Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Neurology

Understanding Your RRMS Diagnosis

At a Glance

RRMS causes episodes of neurological symptoms when immune inflammation damages myelin, followed by periods of improvement. Remission does not mean MS is gone; early disease-modifying treatment and regular MRI follow-up can reduce activity and delay disability.

Receiving a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) is often the end of a long and exhausting journey through unexplained symptoms and clinical testing. It is natural to feel a mix of relief at finally having an answer and anxiety about what that answer means for your future. While the name of the condition sounds daunting, it is important to know that you are entering a medical landscape that has been transformed over the last two decades. MS is no longer the predictable path to immediate disability that it was for previous generations; modern medicine has fundamentally changed the outlook for people living with RRMS [1][2].

Understanding the Biological “Mistake”

RRMS is an immune-mediated disease of the central nervous system (CNS), which includes your brain, optic nerves, and spinal cord. In a healthy body, the immune system protects you from external threats like viruses. In RRMS, specific immune cells called T-cells and B-cells become “autoreactive,” meaning they mistakenly identify your own body as a threat [3][4].

To reach your brain, these cells must cross the blood-brain barrier (BBB), a specialized layer of cells that usually acts as a high-security gatekeeper [5]. In RRMS, this barrier becomes “leaky” or disrupted, allowing inflammatory cells to flood into the CNS [6]. Once inside, they launch an attack on myelin, the protective fatty coating that insulates your nerve fibers (axons) [7].

Think of myelin like the rubber insulation on an electrical cord. When it is damaged, the “electrical” signals traveling through your nerves can slow down, become garbled, or fail to reach their destination entirely. This process of damage is called demyelination [8].

Who Does RRMS Affect?

RRMS is the most common form of Multiple Sclerosis, accounting for approximately 80% to 85% of initial diagnoses [9][10]. It predominantly affects young adults, with symptoms typically appearing between the ages of 20 and 40, though it can be diagnosed earlier or later in life [11][12].

There is a clear demographic trend in who develops this condition:

  • Gender: Women are significantly more likely to be diagnosed than men, with some studies showing a ratio as high as 3 or 4 women for every 1 man [9][12].
  • Age of Onset: While it can vary, the average age at diagnosis is often in the mid-30s [11].

What “Relapsing-Remitting” Actually Means

The term “relapsing-remitting” describes the pattern of how the disease clinically behaves over time. Unlike other forms of MS that may involve a steady decline from the start, RRMS is defined by clear cycles [13]:

  1. Relapses (Flares or Attacks): These are periods of new or worsening neurological symptoms that last at least 24 hours. They are caused by a fresh wave of inflammation and damage in the CNS.
  2. Remissions (Recovery): Following a relapse, symptoms may disappear completely or leave behind some mild, permanent changes.

It is important to understand that “remission” refers to the clinical pattern—meaning no recognized relapse—and does not mean the MS has gone away entirely. You can still experience new silent MRI lesions or accumulate disability independent of relapses (often called progression independent of relapse activity). Modern treatments aim to make these remission periods last as long as possible by preventing new relapses and monitoring progression [13][1].

A New Era of Prognosis

In the past, an MS diagnosis was often associated with an inevitable loss of mobility. However, the introduction of Disease-Modifying Therapies (DMTs) has rewritten this narrative. We now know that starting treatment early can significantly delay or even prevent the accumulation of disability [14][2].

Recent data shows that people treated with modern therapies reach physical milestones (such as needing a walking aid) many years later than those in previous generations [1]. For many, RRMS is now managed as a chronic, controllable condition rather than a rapidly progressing one. Your medical team’s goal is to minimize disease activity and protect your nervous system from future injury [15].

As you move forward, this guide will help you navigate the specifics of your care, from understanding your MRI results to choosing the right treatment strategy for your life. You are not just a passenger in this process; you are the most important member of your care team.

Common questions in this guide

What does a diagnosis of RRMS mean?
RRMS is a form of multiple sclerosis in which immune-system activity damages myelin in the brain, optic nerves, and spinal cord. It typically causes episodes of new or worsening neurological symptoms, called relapses, followed by periods of partial or complete recovery, called remissions.
Does remission mean that RRMS has gone away?
No. Remission means there is no recognized relapse or that symptoms have improved, but MS-related activity can still occur, including new MRI lesions or disability that develops independently of relapses. Regular follow-up helps detect activity and guide treatment.
How do MRI scans help confirm an RRMS diagnosis?
MRI scans and your clinical history help clinicians look for evidence that disease activity has occurred in different areas of the central nervous system and at different times. Ask your care team how your symptoms and MRI findings established this pattern and what your baseline scan shows.
What is an RRMS relapse, and how is it different from remission?
A relapse is a period of new or worsening neurological symptoms caused by fresh inflammation in the central nervous system and lasting at least 24 hours. During remission, symptoms may improve completely or leave lingering changes, but the disease has not necessarily disappeared.
Can starting RRMS treatment early change the long-term outlook?
Starting a disease-modifying therapy early can reduce new disease activity and significantly delay or prevent accumulation of disability. These treatments aim to prevent relapses and protect the nervous system, while the best choice depends on your disease and personal goals.
Who is most likely to develop relapsing-remitting MS?
RRMS is the most common initial form of multiple sclerosis, accounting for about 80% to 85% of initial diagnoses. It often begins in young adults between 20 and 40 and is diagnosed more often in women than men, although it can occur at other ages and in men.

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    How patients with multiple sclerosis acquire disability.

    Lublin FD, Häring DA, Ganjgahi H, et al.

    Brain : a journal of neurology 2022; (145(9)):3147-3161 doi:10.1093/brain/awac016.

    PMID: 35104840
  2. 2

    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.

    Sorensen PS, Sellebjerg F, Hartung HP, et al.

    Brain : a journal of neurology 2020; (143(9)):2637-2652 doi:10.1093/brain/awaa145.

    PMID: 32710096
  3. 3

    The role of the adaptive immune system in the initiation and persistence of multiple sclerosis.

    Afzali AM, Korn T

    Seminars in immunology 2025; (78()):101947 doi:10.1016/j.smim.2025.101947.

    PMID: 40179676
  4. 4

    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response.

    McWilliam O, Sellebjerg F, Marquart HV, von Essen MR

    Journal of neuroimmunology 2018; (324()):157-164 doi:10.1016/j.jneuroim.2018.09.001.

    PMID: 30244922
  5. 5

    Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies.

    Zierfuss B, Larochelle C, Prat A

    The Lancet. Neurology 2024; (23(1)):95-109 doi:10.1016/S1474-4422(23)00377-0.

    PMID: 38101906
  6. 6

    The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis.

    Balasa R, Barcutean L, Balasa A, et al.

    Human immunology 2020; (81(5)):237-243 doi:10.1016/j.humimm.2020.02.009.

    PMID: 32122685
  7. 7

    Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

    Liu R, Du S, Zhao L, et al.

    Frontiers in immunology 2022; (13()):996469 doi:10.3389/fimmu.2022.996469.

    PMID: 36211343
  8. 8

    Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.

    Lassmann H

    Frontiers in immunology 2018; (9()):3116 doi:10.3389/fimmu.2018.03116.

    PMID: 30687321
  9. 9

    Prevalence of multiple sclerosis in Brazil: An updated systematic review with meta-analysis.

    Moura JA, Teixeira LADC, Tanor W, et al.

    Clinical neurology and neurosurgery 2025; (249()):108741 doi:10.1016/j.clineuro.2025.108741.

    PMID: 39826442
  10. 10

    Pediatric onset multiple sclerosis in Kuwait.

    Alroughani R, AlMojel M, Qasem D, et al.

    Clinical neurology and neurosurgery 2025; (248()):108643 doi:10.1016/j.clineuro.2024.108643.

    PMID: 39579683
  11. 11

    Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study.

    Ziemssen T, Hoffmann F, Richter S, et al.

    Frontiers in neurology 2021; (12()):620758 doi:10.3389/fneur.2021.620758.

    PMID: 34421780
  12. 12

    Epidemiological and clinical features of pediatric-onset multiple sclerosis: A population-based study in Isfahan, Iran, between 1997-2020.

    Etemadifar M, Abhari AP, Yadegarfar G, et al.

    Current journal of neurology 2021; (20(4)):222-228 doi:10.18502/cjn.v20i4.8348.

    PMID: 38011448
  13. 13

    Diagnosis and Treatment of Multiple Sclerosis: A Review.

    McGinley MP, Goldschmidt CH, Rae-Grant AD

    JAMA 2021; (325(8)):765-779 doi:10.1001/jama.2020.26858.

    PMID: 33620411
  14. 14

    Consensus on early detection of disease progression in patients with multiple sclerosis.

    Meca-Lallana JE, Casanova B, Rodríguez-Antigüedad A, et al.

    Frontiers in neurology 2022; (13()):931014 doi:10.3389/fneur.2022.931014.

    PMID: 35968319
  15. 15

    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

    Rae-Grant A, Day GS, Marrie RA, et al.

    Neurology 2018; (90(17)):777-788 doi:10.1212/WNL.0000000000005347.

    PMID: 29686116

This page explains RRMS biology, diagnosis, treatment, and outlook for educational purposes; it is not medical advice. Discuss your MRI findings, symptoms, treatment options, and prognosis with your neurologist or MS care team.